Resource Summary

Clinical Question:
Is roflumilast (Daxas®) beneficial as an add-on therapy in the management of COPD?

Bottom-line:
Roflumilast decreases the risk of COPD exacerbations for one in 25^ with no effect on mortality and no clinically important improvements in quality of life. Roflumilast increases the risk of various adverse effects^ including psychiatric (one in 28)^ diarrhea (one in 15)^ and weight loss (one in 17). The net benefit of roflumilast is questionable.


*** Original Documents can be found and downloaded using the link provided below ***

https://www.acfp.ca/tools-for-practice/

Publication Date: 2014-12-12
Last Updated on PCR: 2017-03-31 16:35:04